pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorec
One Amgen Center Drive, Thousand Oaks, CA 91320, US HQ
1980 Founded
40,212 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
20230225
Phase 3 · small molecule · "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"
20230225 for "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity" is a Phase 3 program (small_molecule) at Amgen with 1 ClinicalTrials.gov record(s).
Internal code 20230225
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Amgen
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"
- Status
- active
- Trials
- 1